Table 2 Composite primary endpoint and individual components.

From: Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial

 

Colchicine (n = 119)

Control (n = 120)

OR

95% CI

p

Composite primary endpoint

21 (17.7%)

25 (20.8%)

0.81

0.43–1.55

0.533

CPAP/BiPAP

16 (13.5%)

18 (15.0%)

0.88

0.43–1.82

0.731

ICU admission

11 (9.2%)

14 (11.7%)

0.77

0.33–1.78

0.541

Invasive ventilation

5 (4.2%)

10 (8.3%)

0.48

0.16–1.46

0.196

Death

7 (5.9%)

10 (8.33%)

0.69

0.25–1.87

0.463

  1. CPAP/BiPAP continuous positive airway pressure/bilevel positive airway pressure, ICU intensive care unit.
Back to article page